{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:12Z","timestamp":1786987452553,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5 \\u00D7 1000"],"award-info":[{"award-number":["5 \\u00D7 1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105327","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:24:57Z","timestamp":1775841897000},"page":"105327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): \u2018Where the streets have no name\u2019"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3742-9962","authenticated-orcid":false,"given":"Gianluca","family":"Spitaleri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Trillo Aliaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca Alessio","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Attili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Del Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Corvaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio Maria","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Cavallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian David","family":"Etessami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiu","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Passaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"de Marinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2026.105327_bib1","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1097\/JTO.0b013e3182635ab4","article-title":"EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer","volume":"7","author":"Ackerman","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105327_bib2","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","article-title":"Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity","volume":"22","author":"Ballard","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jtho.2022.10.004","article-title":"UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-line setting (UNICORN)","volume":"18","author":"Bar","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105327_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105327_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jtho.2024.03.016","article-title":"Unveiling the landscape of uncommon EGFR mutations","volume":"19","author":"Borgeaud","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib6","series-title":"2025 World Lung Cancer Conference 2025 Barcelona 6-9; Abs MA08.07","article-title":"OCELOT: A Pan-Canadian Study of Osimertinib for Patients with Treatment Naive Advanced NSCLC with Uncommon EGFR Mutations","author":"Breadner","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105327_bib7","unstructured":"Cancer.gov, Cancer Clinical trials information https:\/\/clinicaltrials.gov\/search?cond=NSCLC&term=EGFR&aggFilters=status:not%20rec&rank=4&page=1&limit=10&sort=@relevance. [accessed September 11, 2025]."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105327_bib8","doi-asserted-by":"crossref","first-page":"8163","DOI":"10.1158\/0008-5472.CAN-06-0453","article-title":"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib","volume":"66","author":"Carey","year":"2006","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105327_bib9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/sj.onc.1209159","article-title":"Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants","volume":"25","author":"Chen","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/JTO.0000000000000504","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X\/L861Q\/S768I Mutations","volume":"10","author":"Chiu","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105327_bib11","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105327_bib12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"MARIPOSA Investigators. Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.19.00931","article-title":"Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, Phase II trial (KCSG-LU15-09)","volume":"38","author":"Cho","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105327_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105327_bib16","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1097\/JTO.0b013e318227e8c6","article-title":"Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations","volume":"6","author":"De Pas","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib17","unstructured":"European Medicines Agency. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/giotrif-epar-product-information_en.pdf\u3009 [accessed 26 Jul 2025]."},{"issue":"7_Supplement","key":"10.1016\/j.critrevonc.2026.105327_bib18","doi-asserted-by":"crossref","first-page":"CT247","DOI":"10.1158\/1538-7445.AM2024-CT247","article-title":"Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study","volume":"84","author":"Fang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105327_bib19","unstructured":"FDA.GOV, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr#:\u223c:text=On%20January%2012%2 C%202018%2 C%20the,confidence%20interval%2047%2 C%2081). [accessed 26 Jul 2025]."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/cas.12125","article-title":"Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors","volume":"104","author":"Furuyama","year":"2013","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105327_bib21","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jtho.2023.09.033","article-title":"OA03.04 A phase 1b study of furmonertinib, an oral, brain penetrant, selective EGFR inhibitor, in patients with advanced NSCLC with EGFR exon 20 insertions","volume":"18","author":"Han","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105327_bib22","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/JTO.0b013e3181e8b3c5","article-title":"Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer","volume":"5","author":"Hata","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105327_bib23","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/s41467-024-45594-4","article-title":"Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants","volume":"15","author":"Hayes","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105327_bib24","article-title":"on behalf of the ESMO Guidelines Committee. Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","author":"Hendriks","year":"2025","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105327_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ijc.22513","article-title":"The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer","volume":"120","author":"Ichihara","year":"2007","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105327_bib26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.annonc.2022.02.225","article-title":"National Network Genomic Medicine Lung Cancer (nNGM). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM)","volume":"33","author":"Janning","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105327_bib27","article-title":"Osimertinib in NSCLC with atypical EGFR-activating mutations: a retrospective multicenter study","volume":"4","author":"Ji","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105327_bib28","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1158\/0008-5472.CAN-05-1829","article-title":"Epidermal growth factor-independent transformation of Ba\/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression","volume":"65","author":"Jiang","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/JTO.0b013e3182021f3e","article-title":"The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors","volume":"6","author":"Kancha","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1078-0432.CCR-08-1757","article-title":"Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy","volume":"15","author":"Kancha","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105327_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s10147-013-0602-1","article-title":"Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer","volume":"19","author":"Keam","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105327_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/JTO.0b013e3182781e35","article-title":"Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors","volume":"8","author":"Kobayashi","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105327_bib33","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1158\/0008-5472.CAN-04-2818","article-title":"Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications","volume":"64","author":"Kosaka","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105327_bib34","unstructured":"Le X.. ES01.06: Approaches to uncommon EGFR mutations. Oral presentation at the IASLC Targeted Therapies of Lung Cancer Meeting (TTLC), February 19-22, 2025, Huntington Beach, CA, USA."},{"key":"10.1016\/j.critrevonc.2026.105327_bib35","article-title":"EGFR PACC mutations occur more frequently in compound than classical mutations with improved responses to TKIs","author":"Le","year":"2024","journal-title":"European Lung Cancer Conference"},{"key":"10.1016\/j.critrevonc.2026.105327_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8666","article-title":"FURTHER: a global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)","volume":"42","author":"Le","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105327_bib37","doi-asserted-by":"crossref","unstructured":"Le X., Yu Y., Zhao Y., Planchard D., Cheng Y., Li X., Gadgeel S., Zhang J., Spira A., Hayashi H., Riess J., Kitazono S., Leighl N., Gao B., Juan-Vidal O., de Langen A.J., Mazieres J., P\u00e9rol M., Jiang Y., Hu T., Huang J., Baio N., Musib L., Kowanetz M., Wang S., Leung W., Yea S., Hsu J., Wang J. FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations. 2024 World Lung Cancer Conference 2024 san Diego September 7-10; abs 1358.","DOI":"10.1016\/j.jtho.2024.09.019"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105327_bib38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/JTO.0b013e318169e341","article-title":"Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation","volume":"3","author":"Ludovini","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105327_bib39","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105327_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105327_bib41","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105327_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105327_bib43","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/jjco\/hyq087","article-title":"Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)","volume":"40","author":"Masago","year":"2010","journal-title":"Jpn J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105327_bib44","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1200\/JCO-24-02007","article-title":"Thoracic Oncology Research Group and all ACHILLES investigators. Pragmatic randomized study of afatinib versus chemotherapy for patients with non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: ACHILLES\/TORG1834","volume":"43","author":"Miura","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib46","doi-asserted-by":"crossref","unstructured":"Musib L., Kowanetz M., Li Q., Luo H.,Hu J., Lutzker S. Furmonertinib is an Oral, Irreversible, Highly Brain Penetrant Pan-EGFR Inhibitor with Activity Against Classical and Atypical EGFR Mutations. 2022 North America Conference on Lung Cancer 23-25 September 2022 Chicago, Illinois: Abs PP01.11.","DOI":"10.1016\/j.jtho.2022.09.037"},{"key":"10.1016\/j.critrevonc.2026.105327_bib47","unstructured":"NCCN guidelines. \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf\u3009 [accessed 22 Mar 2026]."},{"issue":"3-4","key":"10.1016\/j.critrevonc.2026.105327_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000112947","article-title":"Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer","volume":"72","author":"Okami","year":"2007","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105327_bib49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamaoncol.2023.5013","article-title":"First-line osimertinib for previously untreated patients with NSCLC and uncommon EGFR mutations: the UNICORN phase 2 nonrandomized clinical trial","volume":"10","author":"Okuma","year":"2024","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105327_bib50","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.3747\/co.19.908","article-title":"Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation","volume":"19","author":"Ong","year":"2012","journal-title":"Curr. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105327_bib51","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"issue":"5676","key":"10.1016\/j.critrevonc.2026.105327_bib52","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"issue":"S8","key":"10.1016\/j.critrevonc.2026.105327_bib53","article-title":"Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study","volume":"29","author":"Papadimitrakopoulou","year":"2018","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105327_bib54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jtho.2025.05.006","article-title":"Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: a phase II multicenter trial","volume":"20","author":"Park","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib55","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jtho.2020.12.002","article-title":"Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions EGFR mutations","volume":"16","author":"Passaro","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib56","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1200\/JCO-25-00763","article-title":"for the REZILIENT1 Investigators. Zipalertinib in patients with epidermal growth factor receptor exon 20 insertion-positive non\u2013small cell lung cancer previously treated with platinum-based chemotherapy with or without amivantamab","volume":"43","author":"Piotrowska","year":"2025","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105327_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103592","article-title":"Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective observational multicenter study (ARTICUNO)","volume":"9","author":"Pizzutilo","year":"2024","journal-title":"ESMO Open"},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105327_bib58","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"FLAURA2 investigators. osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105327_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"FLAURA Investigators. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7878","key":"10.1016\/j.critrevonc.2026.105327_bib60","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105327_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105327_bib62","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2009.27.9414","article-title":"Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer","volume":"28","author":"Sequist","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105327_bib63","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1056\/NEJMc1506831","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"373","author":"Sequist","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"75","key":"10.1016\/j.critrevonc.2026.105327_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"27","key":"10.1016\/j.critrevonc.2026.105327_bib65","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib66","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/JTO.0b013e31825134ac","article-title":"Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases","volume":"7","author":"Sharma","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105327_bib67","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib68","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105327_bib69","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.1200\/JCO.2005.01.0793","article-title":"Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer","volume":"23","author":"Takano","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105327_bib70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtho.2024.12.012","article-title":"Decoding the clinical and molecular signatures of EGFR common, compound, and uncommon mutations in NSCLC: a brief report","volume":"20","author":"Tavernari","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib71","article-title":"CHRYSALIS-2Cohort C. amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer: results from CHRYSALIS-2","author":"Tomasini","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib72","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa050736","article-title":"Erlotinib in lung cancer - molecular and clinical predictors of outcome","volume":"353","author":"Tsao","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib73","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"ADAURA Investigators. Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105327_bib74","series-title":"Phase 2 Interim Results of Zipalertinib in Patients With NSCLC Harboring Uncommon Non-Exon 20 Insertion EGFR Mutations","author":"Udagawa","year":"2025"},{"key":"10.1016\/j.critrevonc.2026.105327_bib75","series-title":"MCLA-129, an Anti-EGFR\/MET Bispecific Antibody, in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results of a Phase 1 Study","author":"Wang","year":"2025"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib76","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JTO.0000000000000048","article-title":"Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q","volume":"9","author":"Watanabe","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"_1","key":"10.1016\/j.critrevonc.2026.105327_bib77","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105327_bib78","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1158\/1078-0432.CCR-07-5123","article-title":"Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105327_bib79","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105327_bib80","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1634\/theoncologist.2008-0093","article-title":"Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern","volume":"13","author":"Wu","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2026.105327_bib81","article-title":"Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction","volume":"6","author":"Wu","year":"2011","journal-title":"PLoS ONE"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105327_bib82","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"ADAURA Investigators. Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib84","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105327_bib85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105327_bib86","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib87","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: an updated database of 1023 cases brief report","volume":"12","author":"Yang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib88","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac Oncol."},{"key":"10.1016\/j.critrevonc.2026.105327_bib89","doi-asserted-by":"crossref","unstructured":"Yang J.C.H., Kim Y.J., Lee S.H., Liu B., Ostapenko Y., Lu S., Alip A., Korbenfeld E., Dias J.M., Danchaivijitr P., Girard N., Felip E., Hayashi H., Spira A.I., Besse B., Sun T., Ennis M., Sethi S., Bauml J.M., Cho B.C. Amivantamab plus lazertinib vs osimertinib in first-line (1 L) EGFR-mutant (EGFRm) advanced NSCLC: final overall survival (OS) from the phase III MARIPOSA study. Abstract #4 O presented at the European Lung Cancer Congress (ELCC), March 26-29, 2025, Paris, France.","DOI":"10.1016\/S1556-0864(25)00199-6"},{"key":"10.1016\/j.critrevonc.2026.105327_bib90","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations","volume":"43","author":"Yang","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105327_bib91","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105327_bib92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.4161\/cbt.6.5.4003","article-title":"Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors","volume":"6","author":"Yuza","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2026.105327_bib93","article-title":"Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA\/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: preliminary results from a phase 2 study","volume":"43","author":"Zhang","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2026.105327_bib94","article-title":"Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): results from the randomized OptiTROP-Lung03 study","volume":"43","author":"Zhang","year":"2025","journal-title":"JCO"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105327_bib95","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105327_bib96","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/annonc\/mdv276","article-title":"Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)","volume":"26","author":"Zhou","year":"2015","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105327_bib97","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105327_bib98","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T06:57:41Z","timestamp":1780037861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":98,"alternative-id":["S1040842826002143"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105327","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): \u2018Where the streets have no name\u2019","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105327"}}